14.79

1.42% 0.42

Cidara Therapeutics Inc (CDTX)

Overview News Price History Option Chain Financials Discussions Forecast

Cidara Therapeutics Inc stock is traded at $14.79, with a volume of 38,879. It is up +1.42% in the last 24 hours and up +29.44% over the past month. Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Previous Close:

$14.37

Open:

$14.33

24h Volume:

38,879

Relative Volume:

1.94

Market Cap:

$102.39M

Revenue:

$56.54M

Net Income/Loss:

$-30.70M

P/E Ratio:

-37.92

EPS:

-0.39

Net Cash Flow:

$-31.05M

1W Performance:

+9.17%

1M Performance:

+29.44%

6M Performance:

+30.01%

1Y Performance:

-6.57%

1-Day Range:

$14.33

$14.90

1-Week Range:

$13.14

$14.97

52-Week Range:

$10.00

$24.40

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name

Cidara Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

858-752-6170

Address

6310 NANCY RIDGE DRIVE, SAN DIEGO, CA

Employee

Twitter

@CidaraThera

Next Earnings Date

2024-10-31

Latest SEC Filings

CDTX's Discussions on Twitter

Compare CDTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CDTX	14.90	102.39M	56.54M	-30.70M	-31.05M	-0.39
VRTX	467.45	119.83B	10.63B	-479.80M	-1.35B	13.33
REGN	760.74	83.28B	13.85B	4.65B	3.32B	35.06
ARGX	564.72	33.74B	1.86B	-40.29M	-1.28B	-4.16
ALNY	230.44	30.38B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.56	24.08B	3.30B	-501.07M	1.03B	11.54

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-14-24	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-03-21	Resumed	H.C. Wainwright	Buy
Sep-22-21	Upgrade	WBB Securities	Buy → Strong Buy
Mar-04-21	Initiated	Aegis Capital	Buy
Sep-04-19	Upgrade	Wedbush	Neutral → Outperform
Jul-26-18	Initiated	Citigroup	Buy
Apr-21-17	Initiated	Raymond James	Strong Buy
Apr-17-17	Reiterated	H.C. Wainwright	Buy
Apr-12-17	Initiated	Ladenburg Thalmann	Buy
Apr-11-17	Resumed	Wedbush	Outperform
Feb-22-17	Reiterated	H.C. Wainwright	Buy
Feb-22-17	Upgrade	WBB Securities	Sell → Hold
Dec-21-16	Resumed	Leerink Partners	Outperform
Dec-19-16	Initiated	H.C. Wainwright	Buy
Sep-23-16	Downgrade	WBB Securities	Hold → Sell
Oct-09-15	Upgrade	WBB Securities	Sell → Hold
May-11-15	Initiated	Jefferies	Buy
May-11-15	Initiated	Leerink Partners	Outperform
May-11-15	Initiated	Needham	Buy
May-11-15	Initiated	Wedbush	Outperform
Apr-23-15	Initiated	WBB Securities	Sell

View All

Cidara Therapeutics Inc Stock (CDTX) Latest News

Nov 17, 2024

(CDTX) Technical Data - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

HC Wainwright Has Positive Outlook of CDTX FY2024 Earnings - MarketBeat

Nov 14, 2024

Nov 11, 2024

Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at HC Wainwright - MarketBeat

Nov 11, 2024

Nov 08, 2024

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 07, 2024

Cidara's Q3 Loss Widens to $16M Despite Strong CD388 Trial Progress and Cash Position | CDTX Stock News - StockTitan

Nov 07, 2024

Nov 06, 2024

(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 06, 2024

Oct 31, 2024

Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews

Oct 31, 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire

Oct 31, 2024

Oct 30, 2024

How Cidara Got Its Molecule Back - BioProcess Online

Oct 30, 2024

Oct 29, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat

Oct 29, 2024

Oct 23, 2024